x
Filter:
Filters applied
- Accelerated Communications
- RBDRemove RBD filter
- COVID-19Remove COVID-19 filter
Publication Date
Please choose a date range between 2021 and 2021.
Author
- Abrams, Cameron F1
- Adam, Damien1
- Anand, Sai Priya1
- Benlarbi, Mehdi1
- Boivin, Guy1
- Brochiero, Emmanuelle1
- Charest, Hugues1
- Ding, Shilei1
- Fage, Clément1
- Finzi, Andrés1
- Gasser, Romain1
- Gong, Shang Yu1
- Goyette, Guillaume1
- Guo, Youjia1
- Gupta Vergara, Natasha1
- Hirohama, Mikako1
- Kawaguchi, Atsushi1
- Moreira, Sandrine1
- Mothes, Walther1
- Murano, Kensaku1
- Pazgier, Marzena1
- Privé, Anik1
- Prévost, Jérémie1
- Richard, Jonathan1
- Roger, Michel1
JBC Communications
2 Results
- Accelerated Communication Editors' PickOpen Access
Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2
Journal of Biological ChemistryVol. 297Issue 4101151Published online: August 31, 2021- Jérémie Prévost
- Jonathan Richard
- Romain Gasser
- Shilei Ding
- Clément Fage
- Sai Priya Anand
- and others
Cited in Scopus: 19The seasonal nature of outbreaks of respiratory viral infections with increased transmission during low temperatures has been well established. Accordingly, temperature has been suggested to play a role on the viability and transmissibility of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The receptor-binding domain (RBD) of the Spike glycoprotein is known to bind to its host receptor angiotensin-converting enzyme 2 (ACE2) to initiate viral fusion. Using biochemical, biophysical, and functional assays to dissect the effect of temperature on the receptor–Spike interaction, we observed a significant and stepwise increase in RBD-ACE2 affinity at low temperatures, resulting in slower dissociation kinetics. - Accelerated CommunicationOpen Access
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
Journal of Biological ChemistryVol. 296100346Published online: January 29, 2021- Youjia Guo
- Atsushi Kawaguchi
- Masaru Takeshita
- Takeshi Sekiya
- Mikako Hirohama
- Akio Yamashita
- and others
Cited in Scopus: 9Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak in the winter of 2019. An extensive investigation of SARS-CoV-2 is critical for disease control. Various recombinant monoclonal antibodies of human origin that neutralize SARS-CoV-2 infection have been isolated from convalescent patients and will be applied as therapies and prophylaxis. However, the need for dedicated monoclonal antibodies suitable for molecular pathology research is not fully addressed.